Literature DB >> 19824110

Duodenal biopsy may be avoided when high transglutaminase antibody titers are present.

Santiago Vivas1, Jose G Ruiz de Morales, Sabino Riestra, Laura Arias, Dolores Fuentes, Noemi Alvarez, Sara Calleja, Mercedes Hernando, Blanca Herrero, Javier Casqueiro, Luis Rodrigo.   

Abstract

AIM: To evaluate the predictive value of tissue transglutaminase (tTG) antibodies for villous atrophy in adult and pediatric populations to determine if duodenal biopsy can be avoided.
METHODS: A total of 324 patients with celiac disease (CD; 97 children and 227 adults) were recruited prospectively at two tertiary centers. Human IgA class anti-tTG antibody measurement and upper gastrointestinal endoscopy were performed at diagnosis. A second biopsy was performed in 40 asymptomatic adults on a gluten-free diet (GFD) and with normal tTG levels.
RESULTS: Adults showed less severe histopathology (26% vs 63%, P < 0.0001) and lower tTG antibody titers than children. Levels of tTG antibody correlated with Marsh type in both populations (r = 0.661, P < 0.0001). Multiple logistic regression revealed that only tTG antibody was an independent predictor for Marsh type 3 lesions, but clinical presentation type and age were not. A cut-off point of 30 U tTG antibody yielded the highest area under the receiver operating characteristic curve (0.854). Based on the predictive value of this cut-off point, up to 95% of children and 53% of adults would be correctly diagnosed without biopsy. Despite GFDs and decreased tTG antibody levels, 25% of the adults did not recover from villous atrophy during the second year after diagnosis.
CONCLUSION: Strongly positive tTG antibody titers might be sufficient for CD diagnosis in children. However, duodenal biopsy cannot be avoided in adults because disease presentation and monitoring are different.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824110      PMCID: PMC2761554          DOI: 10.3748/wjg.15.4775

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Coeliac disease: a biopsy is not always necessary for diagnosis.

Authors:  P G Hill; G K T Holmes
Journal:  Aliment Pharmacol Ther       Date:  2008-01-11       Impact factor: 8.171

2.  [Usefulness of anti-transglutaminase antibodies in the diagnosis of celiac disease].

Authors:  M L Fernández; S Vivas; J M Ruiz de Morales; J M Marugán
Journal:  Gastroenterol Hepatol       Date:  2005-10       Impact factor: 2.102

3.  Serum IgA antiendomysium antibody titers as a marker of intestinal involvement and diet compliance in adult celiac sprue.

Authors:  C Sategna-Guidetti; R Pulitanó; S Grosso; G Ferfoglia
Journal:  J Clin Gastroenterol       Date:  1993-09       Impact factor: 3.062

Review 4.  Current concepts of celiac disease pathogenesis.

Authors:  D Schuppan
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

5.  Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Ivor D Hill; Martha H Dirks; Gregory S Liptak; Richard B Colletti; Alessio Fasano; Stefano Guandalini; Edward J Hoffenberg; Karoly Horvath; Joseph A Murray; Mitchell Pivor; Ernest G Seidman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-01       Impact factor: 2.839

6.  Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease.

Authors:  K Kaukinen; M Peräaho; K Lindfors; J Partanen; N Woolley; P Pikkarainen; A-L Karvonen; T Laasanen; H Sievänen; M Mäki; P Collin
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

7.  Strongly positive tissue transglutaminase antibodies are associated with Marsh 3 histopathology in adult and pediatric celiac disease.

Authors:  Matthew R Donaldson; Linda S Book; Kristin M Leiferman; John J Zone; Susan L Neuhausen
Journal:  J Clin Gastroenterol       Date:  2008-03       Impact factor: 3.062

8.  Correlation of duodenal histology with tissue transglutaminase and endomysial antibody levels in pediatric celiac disease.

Authors:  Matthew R Donaldson; Sean D Firth; Holly Wimpee; Kristin M Leiferman; John J Zone; Wyatt Horsley; Molly A O'Gorman; W Daniel Jackson; Susan L Neuhausen; Christopher M Hull; Linda S Book
Journal:  Clin Gastroenterol Hepatol       Date:  2007-04-11       Impact factor: 11.382

9.  Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery.

Authors:  Peter J Wahab; Jos W R Meijer; Chris J J Mulder
Journal:  Am J Clin Pathol       Date:  2002-09       Impact factor: 2.493

10.  Chronic hepatitis C virus and celiac disease, is there an association?

Authors:  Lincoln Hernandez; Timothy C Johnson; Afzal J Naiyer; Debby Kryszak; Edward J Ciaccio; Albert Min; Henry C Bodenheimer; Robert S Brown; Allesio Fasano; Peter H Green
Journal:  Dig Dis Sci       Date:  2007-06-05       Impact factor: 3.199

View more
  39 in total

Review 1.  A novel algorithm for the diagnosis of celiac disease and a comprehensive review of celiac disease diagnostics.

Authors:  Orit Rozenberg; Aaron Lerner; Avi Pacht; Maya Grinberg; Dina Reginashvili; Clara Henig; Mira Barak
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 2.  Age-related differences in celiac disease: Specific characteristics of adult presentation.

Authors:  Santiago Vivas; Luis Vaquero; Laura Rodríguez-Martín; Alberto Caminero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 3.  Celiac disease: from etiological factors to evolving diagnostic approaches.

Authors:  Anantdeep Kaur; Olga Shimoni; Michael Wallach
Journal:  J Gastroenterol       Date:  2017-06-19       Impact factor: 7.527

4.  Application of the Biopsy-Sparing ESPGHAN Guidelines for Celiac Disease Diagnosis in Adults: A Real-Life Study.

Authors:  Konstantinos Efthymakis; Mariaelena Serio; Angelo Milano; Francesco Laterza; Antonella Bonitatibus; Marta Di Nicola; Matteo Neri
Journal:  Dig Dis Sci       Date:  2017-07-17       Impact factor: 3.199

5.  Clinical and histopathological correlation of duodenal biopsy with IgA anti-tissue transglutaminase titers in children with celiac disease.

Authors:  Malobika Bhattacharya; Avinash Lomash; Puja Sakhuja; Anand Prakash Dubey; Seema Kapoor
Journal:  Indian J Gastroenterol       Date:  2014-05-24

6.  Prevalence of IgA antitissue transglutaminase antibodies in children with type 1 diabetes mellitus.

Authors:  Samaşca Gabriel; Iancu Mihaela; Butnariu Angela; Andreica Mariana; Dejica Doru
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

7.  Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping.

Authors:  Marcis Leja; Zakera Shums; Liene Nikitina-Zake; Mikus Gavars; Ilze Kikuste; Jay Milo; Ilva Daugule; Jelena Pahomova; Valdis Pirags; Vilnis Dzerve; Janis Klovins; Andrejs Erglis; Gary L Norman
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

8.  Can High Titres of Anti Tissue Transglutaminase Antibodies Reduce the Need for Intestinal Biopsy for Diagnosis of Celiac Disease?

Authors:  Ekta Bansal; Navpreet Kaur; Naveen Mittal
Journal:  Indian J Clin Biochem       Date:  2017-09-13

9.  Identification of a serum transglutaminase threshold value for the noninvasive diagnosis of symptomatic adult celiac disease patients: a retrospective study.

Authors:  Marco Di Tola; Mariacatia Marino; Simone Goetze; Rossella Casale; Sara Di Nardi; Raffaele Borghini; Giuseppe Donato; Antonio Tiberti; Antonio Picarelli
Journal:  J Gastroenterol       Date:  2016-02-29       Impact factor: 7.527

10.  High-titre circulating tissue transglutaminase-2 antibodies predict small bowel villous atrophy, but decision cut-off limits must be locally validated.

Authors:  L Beltran; M Koenig; W Egner; M Howard; A Butt; M R Austin; D Patel; R R Sanderson; S Goubet; F Saleh; J Lavender; E Stainer; M D Tarzi
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.